Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
临床相关剂量的 FLT3 激酶抑制剂奎扎替尼和米哚妥林不会损害 T 细胞反应性和功能
期刊:Haematologica
影响因子:8.2
doi:10.3324/haematol.2014.104331
Denise Wolleschak, Thomas S Mack, Florian Perner, Stephanie Frey, Tina M Schnöder, Marie-Christine Wagner, Christine Höding, Marina C Pils, Andreas Parkner, Stefanie Kliche, Burkhart Schraven, Katrin Hebel, Monika Brunner-Weinzierl, Satish Ranjan, Berend Isermann, Daniel B Lipka, Thomas Fischer, Flo